Search

everythinglearnresearchcommunity

for

Search:↓

Minoxidil can help grow hair and make hair follicles bigger, but it can also cause side effects.

The "color-transition sign" helps tell apart alopecia areata incognita from telogen effluvium by looking at hair color changes.

COVID-19 recovery can lead to temporary hair loss called telogen effluvium.

The document describes how to tell different types of non-scarring hair loss apart by looking at hair and scalp tissue under a microscope.

A woman experienced temporary hair loss after taking albendazole, which resolved on its own within 3 months.

The document concludes that proper diagnosis and FDA-approved treatments for different types of hair loss exist, but treatments for severe cases often fail and future improvements may focus on hair follicle stem cells.

Hair usually grows back 1-3 months after treatment for anagen effluvium, and children with Loose Anagen Hair Syndrome often improve by adolescence.

Most hair loss disorders can be accurately diagnosed and treated in an outpatient setting.

COVID-19 may cause hair loss and scalp pain due to inflammation and changes in hair follicle receptors, but these symptoms typically resolve in 2 to 4 months.

Minoxidil, finasteride, and low-level laser light therapy are effective FDA-approved treatments for hair loss.

The document explains hair and nail biology, common hair loss conditions and treatments, oral and genital skin diseases, and the risks and treatments associated with squamous cell carcinoma.

Half of people with Alopecia Areata may see hair regrowth within a year without treatment, but recovery is unpredictable.

Minoxidil and finasteride treat hair loss; more research needed for other options.

The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.

Scalp cooling can help prevent chemotherapy-induced hair loss with a 50-90% success rate and is safe for patients.

Diagnosing hair loss disorders needs clinical, dermoscopic, and histological differences, and checking menstrual cycle, weight changes, drug therapy, and nail changes.

We need better treatments for hair loss, and while test-tube methods are helpful, they can't fully replace animal tests for evaluating new hair growth treatments.

Alopecia areata is a hair loss condition caused by immune factors and can be treated with JAK inhibitors.

Prolactin affects hair growth and skin conditions, and could be a target for new skin disease treatments.

No treatment fully prevents hair loss from chemotherapy yet.

Accurate diagnosis is key for treating different kinds of hair loss, and immune response variations may affect the condition and treatment results.

Hair loss in cancer patients can be related to the cancer itself, treatment, or other conditions, and understanding it is important for diagnosis and patient care.

Hair restoration has evolved from surgery to drugs to potential gene therapy, with improved results and ongoing research driven by high demand.

Organs like hair follicles can renew themselves in complex ways, adapting to different needs and environments.

The Itpr3 gene causes a specific hair pattern in mice.

Removing a specific gene in certain skin cells causes hair loss on the body by disrupting normal hair development.

Shorter, thinner hairs indicate AGA, while longer, thicker hairs suggest CTE; counting and measuring shed hairs helps diagnose hair loss type.

Plant extracts like Avicennia marina, Boehmeria nipononivea, and Camellia sinensis could potentially treat hair loss with fewer side effects than synthetic drugs.

Low iron levels are significantly linked to hair loss in women.

Male pattern hair loss may be linked to the developmental origins of hair follicles.